Who are Pivlaz's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Opsumit, Letairis, Tracleer, Azo Gantrisin, Gantrisin, Ambrisentan plus Spironolactone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clazosentan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pivlaz — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivlaz (CLAZOSENTAN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Endothelin-1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pivlaz (CLAZOSENTAN) — Idorsia Pharmaceuticals Japan Ltd.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pivlaz TARGET	CLAZOSENTAN	Idorsia Pharmaceuticals Japan Ltd	marketed		Endothelin-1 receptor
Opsumit	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01
Tracleer	BOSENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist	Endothelin-1 receptor	2001-01-01
Azo Gantrisin	sulfafurazole	Alra	marketed	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Gantrisin	SULFISOXAZOLE ACETYL	Roche	marketed		Endothelin B receptor, Endothelin-1 receptor, Dihydropteroate synthase	1953-01-01
Ambrisentan plus Spironolactone	Ambrisentan plus Spironolactone	Brigham and Women's Hospital	marketed	Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination	Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-28 — Tracleer · 7959945 · Formulation · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pivlaz — Competitive Intelligence Brief. https://druglandscape.com/ci/clazosentan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing